司美格鲁肽治疗超重和肥胖非糖尿病人群的临床应用分析  

Clinical application analysis of semaglutide in the treatment of overweight or obesity without diabetes population

作　　者：崔艳丽 武峰[2] 戴玉洋 CUI Yan-li;WU Feng;DAI Yu-yang(Department of Pharmacy,Shijingshan Teaching Hospital of Capital Medical University,Beijing Shijingshan Hospital,Beijing Shijingshan Hospital,Beijingg100040,China;National Institute for Drug Clinical Trial,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China)

机构地区：[1]首都医科大学石景山教学医院北京市石景山医院药剂科,北京100040 [2]首都医科大学附属北京同仁医院国家药物临床试验机构,北京100730

出　　处：《中国临床药理学杂志》2024年第14期2129-2133,共5页The Chinese Journal of Clinical Pharmacology

摘　　要：目的评价司美格鲁肽治疗超重和肥胖非糖尿病人群的临床疗效及安全性。方法计算机检索PubMed、Embase、Cochrane Library、知网、维普、万方数据库,试验组给予司美格鲁肽治疗,对照组给予安慰剂或其他药物进行治疗。用RevMan 5.4软件对体质量、体质量指数(BMI)、腰围、血压、血糖、血脂等指标变化,以及药物不良反应发生率等进行Meta分析。结果最终共纳入8项研究4671例样本。试验组和对照组的体质量变化分别为(-13.79±19.49)和(-1.74±18.89)kg,体质量变化百分比分别为(-13.67±17.36)%和(-1.04±17.06)%,BMI变化值分别为(-4.99±6.55)和(-0.56±6.64)kg·m^(-2),腰围变化值分别为(-12.11±16.85)和(-3.15±16.46)cm,收缩压变化分别为(-4.97±22.84)和(-0.46±21.83)mmHg,舒张压变化值分别为(-2.58±15.69)和(-0.50±15.14)mmHg,空腹血糖变化值分别为(-7.37±22.34)和(0.87±21.57)mg·mL^(-1),总胆固醇变化百分比分别为(-0.96±25.30)%和(4.38±25.88)%,低密度脂蛋白胆固醇变化百分比分别为(-3.28±38.48)%和(2.67±38.71)%,VLDL-C变化百分比分别为(-15.94±59.35)%和(2.65±67.55)%,三酰甘油变化百分比分别为(-15.96±59.30)%和(2.49±67.15)%,在统计学上差异均有统计意义(均P<0.01)。试验组和对照组的总药物不良反应发生率分别为89.02%和85.56%,在统计学上差异有统计学意义(P<0.05)。结论司美格鲁肽用于超重和肥胖非糖尿病人群的临床疗效确切,对血压、血糖、血脂均有改善作用,消化系统相关药物不良反应发生率相对较高。Objective To systemically evaluate the efficacy and safety of semaglutide on overweight or obesity without diabetes.Methods Database including PubMed,Embase,Cochrane Library,CNKI,VIP and WanFang were searched.Semaglutide was administered in the treatment group,while placebo or other drug were administered in the control group.The Meta-analysis was performed using RevMan 5.4 software to access the changes of weight,body mass index(BMI),waist circumference,blood pressure,blood glucose,blood lipid and the incidence of adverse reactions.Results A total of 8 researches(4671 subjects)were eligible.The weight of the treatment group and control group varied respectively at(-13.79±19.49)and(-1.74±18.89)kg the percents of weight change were(-13.67±17.36)and(-1.04±17.06)%,BMI varied at(-4.99±6.55)and(-0.56±6.64)kg·m^(-2),waist circumference varied at(-12.11±16.85)and(-3.15±16.46)cm,systolic pressure varied at(-4.97±22.84)and(-0.46±21.83)mmH g,diastolic pressure varied at(-2.58±15.69)and(-0.50±15.14)mmH g,the fasting blood glucose varied at(-7.37±22.34)and(0.87±21.57)mg·mL,total cholesterol changed by(-0.96±25.30)%and(4.38±25.88)%,low-density lipoprotein cholesterol changed by(-3.28±38.48)%and(2.67±38.71)%,VLDL-C changed by(-15.94±59.35)%and(2.65±67.55)%,triglyceride changed by(-15.96±59.30)%and(2.49±67.15)%,and the above differences between two groups were significant(P<0.01).The adverse reaction incidences of the treatment group and control group were 89.02%and 85.56%respectively with significant difference(P<0.05).Conclusion In treatment of overweight or obesity without diabetes,semaglutide is proved to have obvious efficacy and can also improve blood pressure,blood glucose and lipid.The gastrointestinal reaction incidence is relatively high.

关 键 词：司美格鲁肽 超重 肥胖 非糖尿病人群 临床疗效 安全性评价 

分 类 号：R977.15[医药卫生—药品]